U.S. market Closed. Opens in 7 hours 54 minutes

DNLI | Denali Therapeutics Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-31
Revenue330.53M108.46M48.66M335.66M26.68M129.16MN/AN/AN/A
Cost of Revenue16.73M7.03M5.61M212.62M193.38M7.42M3.08M1.47M121.00K
Gross Profit313.81M101.43M43.05M123.04M-166.70M121.75M-3.08M-1.47M-121.00K
Operating Expenses527.23M449.21M344.41M272.94M239.86M175.53M90.14M87.43M16.68M
Selling, General & Admin103.35M90.47M79.06M60.33M46.48M32.35M15.68M11.73M5.11M
Research & Development423.88M358.73M265.35M212.62M193.38M143.18M74.46M75.70M11.57M
Other Operating ExpensesN/AN/AN/AN/AN/AN/AN/AN/AN/A
Operating Income-196.70M-340.74M-295.75M62.72M-213.18M-46.37M-90.14M-87.43M-16.68M
Other Expenses / Income51.51M14.77M4.59M9.24M15.22M10.13M1.96M781.00K-109.00K
Before Tax Income-145.19M-325.97M-291.16M71.96M-197.97M-36.24M-88.19M-86.65M-16.79M
Income Tax Expenses30.00K21.00K-575.00K823.00K-351.00K10.13M-3.08MN/AN/A
Net Income-145.22M-325.99M-290.58M71.14M-197.61M-36.24M-88.19M-86.65M-16.79M
Interest ExpensesN/A14.77MN/AN/A15.22MN/A1.96MN/A109.00K
Basic Shares Outstanding137.37M125.53M121.52M108.97M95.61M92.62M14.96M6.42M3.01M
Diluted Shares Outstanding137.37M125.53M121.52M112.70M95.61M92.62M14.96M6.42M3.01M
EBITDA-179.97M-330.36M-287.16M62.72M-205.19M-38.96M-87.06M-85.96M-15.06M
EBITDA Margin-54.45%-304.58%-590.12%18.69%-769.15%-30.16%0.00%0.00%0.00%
EBIT-145.19M-311.20M-291.16M71.96M-182.75M-26.11M-89.31M-86.65M-16.68M
EBIT Margin-43.93%-286.91%-598.34%21.44%-685.01%-20.21%0.00%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙